Hitting the target in IDH2 mutant AML
- PMID: 28798056
- DOI: 10.1182/blood-2017-06-790394
Hitting the target in IDH2 mutant AML
Conflict of interest statement
Conflict-of-interest disclosure: The author declares no competing financial interests.
Comment on
-
Enasidenib induces acute myeloid leukemia cell differentiation to promote clinical response.Blood. 2017 Aug 10;130(6):732-741. doi: 10.1182/blood-2017-04-779447. Epub 2017 Jun 6. Blood. 2017. PMID: 28588019 Free PMC article. Clinical Trial.
-
Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia.Blood. 2017 Aug 10;130(6):722-731. doi: 10.1182/blood-2017-04-779405. Epub 2017 Jun 6. Blood. 2017. PMID: 28588020 Free PMC article. Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous